Abstract:Influenza is a highly contagious disease that causes annual epidemics and occasional pandemics. Birds are believed to be the source of newly emerging pandemic strains, including highly pathogenic avian influenza viruses of the subtype H7. The aim of the study: to evaluate the ability of the recombinant human adenovirus, serotype 5, which expresses genes of influenza A highly conserved antigens (ion channel M2 and nucleoprotein NP), to provide protection to laboratory mice against infection with a lethal dose of avian influenza virus, subtype H7. To achieve this goal, it was necessary to adapt influenza A virus, subtype H7 for reproduction in the lungs of mice, to characterise it, and to use it for evaluation of the protective properties of the recombinant adenovirus. Materials and methods: avian influenza virus A/Chicken/NJ/294508-12/2004 (H7N2) was adapted for reproduction in the lungs of mice by repeated passages. The adapted strain was sequenced and assessed using hemagglutination test, EID50 and LD50 for laboratory mice. BALB/c mice were immunised once with Ad5-tet-M2NP adenovirus intranasally, and 21 days after the immunisation they were infected with a lethal dose (5 LD50) of influenza virus A/Chicken/NJ/294508-12/2004 (H7N2) in order to assess the protective properties of the recombinant adenovirus. The level of viral shedding from the lungs of the infected mice was evaluated by titration of the lung homogenates in MDCK cell culture on days 3 and 6 after infection. The level of specific antibodies to H7 avian influenza virus was determined by indirect enzyme immunoassay. Results: the use of Ad5-tet-M2NP adenovirus for immunisation of the mice ensured 100% survival of the animals that had disease symptoms (weight loss) after their infection with the lethal dose (5 LD50) of H7 avian influenza virus. The study demonstrated a high post-vaccination level of humoral immune response to H7 avian influenza virus. The virus titer decreased significantly by day 6 in the lungs of mice that had been immunised with Ad5-tet-M2NP compared to the control group. Conclusion: the Ad5-tetM2NP recombinant adenovirus can be used to create a candidate pandemic influenza vaccine that would protect against avian influenza viruses, subtype H7, in particular.

Construction of Replication-defective Recombinant Adenoviruses Expressing Influenza Virus Hemagglutinin and Study on Its Immune Responses

[Expression of NA of Influenza Virus and C3d Fusion Gene in Replication-Defective Recombinant Adenovirus and Its Immune Efficacy Analysis].

Expression of H5N1 influenza virus hemagglutinin protein fused with protein transduction domain in an alphavirus replicon system.

Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1).

Recombinant influenza virus carrying human adenovirus epitopes elicits protective immunity in mice

[Expression of influenza B virus hemagglutinin and its immunogenicity determination]

Construction and Immunogenic Evaluation of DNA Vaccine Expressing Influenza A (H1N1) Virus Hemagglutinin Antigen

Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection

[Study on the Immunogenicity of Adeno-Vector Vaccine Against H5N1 Influenza A Virus].

Construction of Eukaryotic Expression Vector with mBD1-mBD3 Fusion Genes and Exploring Its Activity against Influenza A Virus

Hemagglutinin-targeting Artificial MicroRNAs Expressed by Adenovirus Protect Mice From Different Clades of H5N1 Infection

Construction and expression of avian influenza virus HA gene eukaryotic vectors

The protective effect of intranasal immunization with influenza virus recombinant adenovirus vaccine on mucosal and systemic immune response

A Recombinant Protein Containing Highly Conserved Hemagglutinin Residues 81-122 of Influenza H5N1 Induces Strong Humoral and Mucosal Immune Responses.

A replication-deficient H9N2 influenza virus carrying H5 hemagglutinin conferred protection against H9N2 and H5N1 influenza viruses in mice

Construction of Recombinant Adenoviras Expressing RSV F Gene

Recombinant Hemagglutinin Protein from H9N2 Avian Influenza Virus Exerts Good Immune Effects in Mice

Immune Effects Against Influenza A Virus and a Novel DNA Vaccine with Co-Expression of Haemagglutinin- and Neuraminidase-Encoding Genes.

Construction and Immunogenicity Evaluation of Recombinant Bacillus subtilis Expressing HA1 Protein of H9N2 Avian Influenza Virus

Protecting Mice from H7 Avian Influenza Virus by Immunisation with a Recombinant Adenovirus Encoding Influenza A Virus Conserved Antigens

Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses